| Phase 15 trials |
|
Phase 1
|
NCT07429331 |
Mar 2026 |
— |
Cascade Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06888115 |
Mar → May 2025 |
primary biliary cholangitis |
Cascade Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06098027 |
Oct → Nov 2023 |
primary biliary cholangitis |
Cascade Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05624294 |
Dec 2022 → Mar 2023 |
primary biliary cholangitis |
Cascade Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05082779 |
Oct 2021 → Sep 2022 |
primary sclerosing cholangitis |
Cascade Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT05896137 |
Aug 2023 → Nov 2025 overdue |
primary sclerosing cholangitis |
Cascade Pharmaceuticals, Inc |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05896124 |
Aug 2023 → Dec 2025 overdue |
primary biliary cholangitis |
Cascade Pharmaceuticals, Inc |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05591079 |
Feb → Nov 2023 |
metabolic dysfunction-associated steatohepatitis |
Cascade Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07282353 |
Dec 2025 → Dec 2027 expected |
primary biliary cholangitis |
Cascade Pharmaceuticals, Inc |
Recruiting
|
No outcome recorded
|